SRR1440356
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.583
- INFLAMMATORY_RESPONSE+0.536
- IL6_JAK_STAT3_SIGNALING+0.525
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.502
- HYPOXIA+0.480
- ANGIOGENESIS+0.477
- P53_PATHWAY+0.459
- INTERFERON_GAMMA_RESPONSE+0.449
- APOPTOSIS+0.448
- CHOLESTEROL_HOMEOSTASIS+0.437
Top 10 suppressed
- E2F_TARGETS-0.320
- PROTEIN_SECRETION-0.318
- G2M_CHECKPOINT-0.310
- DNA_REPAIR-0.237
- MITOTIC_SPINDLE-0.202
- OXIDATIVE_PHOSPHORYLATION-0.169
- MYC_TARGETS_V2-0.147
- UV_RESPONSE_DN-0.100
- NOTCH_SIGNALING-0.095
- WNT_BETA_CATENIN_SIGNALING-0.091
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1355595 | GTEX | — | 0.973 |
| 2 | SRR1445514 | GTEX | — | 0.955 |
| 3 | SRR663693 | GTEX | — | 0.938 |
| 4 | SRR1323196 | GTEX | — | 0.937 |
| 5 | SRR1498550 | GTEX | — | 0.937 |
| 6 | SRR1374414 | GTEX | — | 0.932 |
| 7 | SRR1407315 | GTEX | — | 0.924 |
| 8 | SRR1347688 | GTEX | — | 0.921 |
| 9 | BS_769BDPDB | pilocytic astrocytoma | — | 0.921 |
| 10 | SRR1488349 | GTEX | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.583 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.536 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.525 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.502 | Inavolisib | — uncovered |
| HYPOXIA | 0.480 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.477 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.459 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.449 | Idelalisib | — uncovered |
| APOPTOSIS | 0.448 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.437 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.411 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.393 | Idelalisib | — uncovered |
| COMPLEMENT | 0.391 | Inavolisib | — uncovered |
| COAGULATION | 0.388 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.383 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.367 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.364 | Inavolisib | — uncovered |
| MYOGENESIS | 0.351 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.348 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.341 | Inavolisib | — uncovered |